Andrew Arno - 01 Jul 2024 Form 4 Insider Report for Oncocyte Corp (OCX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCX	Option to Purchase Common Stock	Award	$0	+30K		$0.00	30K	01 Jul 2024	Common Stock	30K	$2.95	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.